| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 23 Apr 2025 | 15 Apr 2025 |
| Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/04/2025 ,inter alia, to consider and approve Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2025, and to recommend the final dividend, if any, for the financial year 2024-25. Outcome of Board Meeting held on April 23, 2025 Please find attached herewith Intimation herewith for the appointment of Secretarial Auditors and re-appointment of Cost Auditor. (As per BSE Announcement Dated on 23/04/2025) | ||
| Board Meeting | 23 Jan 2025 | 16 Jan 2025 |
| Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2025 inter alia to consider and approve Unaudited Standalone and Consolidated Financial results for Quarter ended December 31 2024. Thyrocare Technologies Ltd has informed BSE regarding Outcome of Board Meeting of the Company held on January 23, 2025. Please find attached herewith Unaudited Standalone and Consolidated for Quarter and Nine months ended December 31,2024. Attached is herewith Intimation for retirement of Mr. Ramjee Dorai as Company Secretary and Compliance Officer with effective January 31, 2025. Attached is herewith intimation for appointment of Mr. Brijesh Kumar as Company Secretary and Compliance Officer of the Company wef January 31, 2025. (As Per BSE Announcement Dated on: 23/01/2025) | ||
| Board Meeting | 23 Oct 2024 | 16 Oct 2024 |
| Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2024 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter and half year ended September 30 2024. Financial Results for September 30, 2024 (As Per BSE Announcement Dated on: 23/10/2024) | ||
| Board Meeting | 23 Jul 2024 | 17 Jul 2024 |
| Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2024 inter alia to consider and approve Board Meeting Intimation for Consideration and Approval of The Unaudited (Standalone & Consolidated) Financial Results of The Company For The Quarter ended June 30 2024. The Board has, at its meeting held today i.e. July 23, 2024, inter alia, considered and approved the unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2024. (As Per BSE Announcement dated on 23.07.2024) | ||
| Board Meeting | 14 May 2024 | 7 May 2024 |
| Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2024 inter alia to consider and approve the Audited (Standalone & Consolidated) Financial Results of the Company for the quarter and financial year ended March 31 2024 and to consider Recommending Final Dividend If any we wish to inform you that the Board has at its meeting held today i.e. May 14, 2024, inter alia, considered and approved the audited financial results (standalone and consolidated) for the quarter and financial year ended on March 31, 2024. Pursuant to Regulation 33(3) of SEBI Listing Regulations, the standalone and consolidated audited financial results for the quarter and financial year ended on March 31, 2024, along with the Audit Reports on said financial results issued by the Statutory Auditors of the Company, are attached as Annexure - A. The Board has recommended a final Dividend of Rs. 18/- per equity share of face value of Rs. 10/- each for the financial year 2023-24, for approval at the ensuing Annual General Meeting. The Board of directors of the Company at their meeting held on May 14, 2024, approved the appointment of Mr. Anandh Sundar and Mr. Nishant Shah as additional director designated as Independent Director wef June 15, 2024 Please find attached herewith Audited financial results for the Quarter and year ended 31 March 2024. The Board has recommended a final dividend for Rs.18/- per share for the financial year 2023-24 for approval at ensuing Annual General Meeting (As per BSE Announcement Dated on 14/05/2024) Newspaper Advertisement - Disclosure under Regulation 30 and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (As Per BSE Announcement Dated on 16/05/2024) | ||
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
